Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for RIFAPENTINE
- 1HP Versus 3HR in the Treatment of Tuberculosis Infection in Vietnam
- Pharmacokinetics and Safety of Double-dose Dolutegravir When Used With Rifapentine for HIV-associated Tuberculosis
- The Safety, Completion Rate and Prevention Effect by Rifamycin-containing Regimens for Latent Tuberculosis Infection in Patients With Kidney Transplantation: a Prospective Intervention Pilot Study
- Sitafloxacin-containing Regimens for Shortening Tuberculosis Treatment
- One-month Latent Tuberculosis Treatment for Renal Transplant Candidates
- Rifapentine and Isoniazid TB Preventive Therapy (3HP) for Children Taking Dolutegravir-based Antiretroviral Treatment (DOLPHIN KIDS)
- Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
- Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
- Short-course Rifamycin-based Regimens for Latent Tuberculosis in Patients With End-stage Kidney Disease
- Evaluation of the Efficacy and Safety of a 4-month Daily Regimen (2HZPM/2HPM) for Treatment of Pulmonary TB
- Treatment Success and Safety of 4 Weeks of Daily Rifapentine and Isoniazid (1HP) vs. 12 Weeks of Weekly Rifapentine and Isoniazid (3HP) for Prevention of Tuberculosis in HIV-uninfected Individuals (1v3HP for TPT in HIV-uninfected Individuals)
- Preventive Treatment Of Latent Tuberculosis Infection In People With Diabetes Mellitus
- A Study of the Pharmacokinetic and Pharmacodynamic Interactions Between Bictegravir, Tenofovir Alafenamide and Rifapentine in Healthy Adult Subjects
- Short Course Rifapentine and Isoniazid for the Preventive Treatment for Latent Genital Tuberculosis
- Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study
- Drug-Drug Interactions Between Rifapentine and Dolutegravir in HIV/LTBI Co-Infected Individuals
- Risk of SDRs Under 3HP and 1HP Regimen for LTBI
- Short Course Rifapentine and Isoniazid for the Preventive Treatment of Tuberculosis(SCRIPT-TB)
- Doravirine, Rifapentine and Isoniazid Interaction
- Tuberculosis Preventive Therapy Among Latent Tuberculosis Infection in HIV-infected Individuals
- Tuberculosis Clinical Trials Consortium Study 35
- Impact of Weekly Administration of Rifapentine and Isoniazid on Steady State Pharmacokinetics of Tenofovir Alafenamide in Healthy Volunteers (YODA)
- Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for Drug-sensitive Tuberculosis
- Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- Treatment of Latent Tuberculosis in Socially Marginalised Citizens
- Addiction, HIV and Tuberculosis in Malaysian Criminal Justice Settings
- Evaluation of the Effect of 3HP vs Periodic 3HP vs 6H in HIV-Positive Individuals
- Impact of Once-Weekly Rifapentine and Isoniazid on the Steady State Pharmacokinetics of Dolutegravir and Darunavir Boosted With Cobicistat in Healthy Volunteers
- The Correlate of Risk Targeted Intervention Study
- Taima TB: 3HP Study
- Evaluating PK, Tolerability, and Safety of Rifapentine and Isoniazid in Pregnant and Postpartum Women
- Pharmacokinetic and Pharmacodynamic Study of High-Dose Rifapentine and Moxifloxacin for Treatment of Tuberculosis
- Efficacy of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention
- TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens
- Immunologic Effects of HCV Therapy With HARVONI in HCV Genotype 1 Chronically Mono-infected Active and Former IDUs
- PK Interaction Between Rifapentine or Rifampicin and a Single Dose of TMC207 in Healthy Subjects (TMC207-CL002)
- Toward a Safe and Reachable Preventive Therapy for LTBI: a Multicenter Randomized Controlled Study in Taiwan
- Patients Response to Early Switch To Oral:Osteomyelitis Study
- Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
- Efficacy and Safety of Concomitant Use of Nevirapine and Rifampicin With HIV-TB
- Interaction Study to Assess the Pharmacokinetic Interaction of Oral Administration of Rifapentine on ATRIPLA™ in HIV Patients
- Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT
- Evaluating the Pharmacokinetics of High-Dose Rifapentine When Given as a Single Dose or in Divided Doses to Healthy Adults
- Brief Rifapentine-Isoniazid Evaluation for TB Prevention (BRIEF TB)
- Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers
- High Dose Rifapentine Pharmacokinetics, Tolerability and Safety Dosage Rifapentine for Treatment of Tuberculosis
- Study of Daily Rifapentine for Pulmonary Tuberculosis
- The Effect of Rifapentine on Raltegravir
- Rifapentine Plus Moxifloxacin for Treatment of Pulmonary Tuberculosis
- TBTC Study 29: Rifapentine During Intensive Phase Tuberculosis (TB) Treatment
- Pharmacokinetic Issues of Moxifloxacin Plus Rifapentine
- A Randomized Trial of DOTS Versus Enhanced DOTS for Community Control of Tuberculosis
- TBTC Study 26 PK: Rifapentine Pharmacokinetics in Children During Treatment of Latent TB Infection
- Tuberculosis Prevention for HIV Infected Adults
- Three Months of Weekly Rifapentine and Isoniazid for M. Tuberculosis Infection
- TBTC Study 25: Study of the Tolerability of Higher Doses of Rifapentine in the Treatment of Tuberculosis
- TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine
- TBTC Study 22: Efficacy of Once-Weekly Rifapentine and Isoniazid in Treatment of Tuberculosis
- Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.
Clinical trials list
click for details